The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Recently, GSK announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older.

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older populations.

Respiratory syncytial virus vaccine market size, growth trends & forecast to reach over USD 15.9 Bn by 2035, driven by rising infection rates and vaccine innovation.

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

Since September 2023, GSK’s RSV vaccine has been approved in Japan for adults aged 60 and over for the prevention of RSV disease.

Since September 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over. The regulatory expansion was supported by results from a global phase III trial.

New data for AREXVY, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease ...